ResearcherAir Force Medical UniversityActive in the last 2 years

Changhong Shi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7490-3593; OpenAlex author ID A5000001452. Sources: OpenAlex.

Their work

Papers: 6 (first author 0, last author 4)
Trials: 0
Grants: 0
Labs led: 1
Collaborators: 11

Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: 2 papers · 2023: 1 paper · 2024: none · 2025: 2 papers

Papers 6

Engineered Bacteria Manipulate Cysteine Metabolism to Boost Ferroptosis-Based Pancreatic Ductal Adenocarcinoma Therapy. Co-author DOI 10.1002/adma.202412982 ↗
Combining molecular characteristics and therapeutic analysis of PDOs predict clinical responses and guide PDAC personalized treatment. Last author DOI 10.1186/s13046-025-03332-8 ↗
Establishment of organoid models for pancreatic ductal adenocarcinoma and screening of individualized therapy strategy. Co-author DOI 10.1002/ame2.12352 ↗
Lipocalin 2 may be a key factor regulating the chemosensitivity of pancreatic cancer to gemcitabine. Last author DOI 10.1016/j.bbrep.2022.101291 ↗
LRRC8A Is a Promising Prognostic Biomarker and Therapeutic Target for Pancreatic Adenocarcinoma. Last author DOI 10.3390/cancers14225526 ↗
Mediated Imaging and Improved Targeting of Farnesylthiosalicylic Acid Delivery for Pancreatic Cancer via Conjugation with Near-Infrared Fluorescence Heptamethi… Last author DOI 10.1021/acsabm.9b01068 ↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Jiaze An · 3 shared papers, 2020–2023 · strength 0.47
Yong Zhao · 2 shared papers, 2022 · strength 0.32
- Paper Lipocalin 2 may be a key factor regulating the chemosensitivity of pancreatic cancer to gemcitabine. DOI 10.1016/j.bbrep.2022.101291 ↗
- Paper LRRC8A Is a Promising Prognostic Biomarker and Therapeutic Target for Pancreatic Adenocarcinoma. DOI 10.3390/cancers14225526 ↗
He Zhang · 2 shared papers, 2020–2022 · strength 0.27
- Paper Lipocalin 2 may be a key factor regulating the chemosensitivity of pancreatic cancer to gemcitabine. DOI 10.1016/j.bbrep.2022.101291 ↗
- Paper Mediated Imaging and Improved Targeting of Farnesylthiosalicylic Acid Delivery for Pancreatic Cancer via Conjugation wi… DOI 10.1021/acsabm.9b01068 ↗
Peng Li · 1 shared paper, 2025 · strength 0.26
- Paper Combining molecular characteristics and therapeutic analysis of PDOs predict clinical responses and guide PDAC personal… DOI 10.1186/s13046-025-03332-8 ↗
Chaoqiang Qiao · 1 shared paper, 2025 · strength 0.22
- Paper Engineered Bacteria Manipulate Cysteine Metabolism to Boost Ferroptosis-Based Pancreatic Ductal Adenocarcinoma Therapy. DOI 10.1002/adma.202412982 ↗
Zhongliang Wang · 1 shared paper, 2025 · strength 0.22
- Paper Engineered Bacteria Manipulate Cysteine Metabolism to Boost Ferroptosis-Based Pancreatic Ductal Adenocarcinoma Therapy. DOI 10.1002/adma.202412982 ↗
Wei Wei · 1 shared paper, 2025 · strength 0.22
- Paper Engineered Bacteria Manipulate Cysteine Metabolism to Boost Ferroptosis-Based Pancreatic Ductal Adenocarcinoma Therapy. DOI 10.1002/adma.202412982 ↗
Peng Li · 1 shared paper, 2023 · strength 0.19
- Paper Establishment of organoid models for pancreatic ductal adenocarcinoma and screening of individualized therapy strategy. DOI 10.1002/ame2.12352 ↗
Miaomiao Gong · 1 shared paper, 2023 · strength 0.19
- Paper Establishment of organoid models for pancreatic ductal adenocarcinoma and screening of individualized therapy strategy. DOI 10.1002/ame2.12352 ↗
Rong Xu · 1 shared paper, 2022 · strength 0.16
- Paper LRRC8A Is a Promising Prognostic Biomarker and Therapeutic Target for Pancreatic Adenocarcinoma. DOI 10.3390/cancers14225526 ↗
Ya Zhao · 1 shared paper, 2020 · strength 0.11
- Paper Mediated Imaging and Improved Targeting of Farnesylthiosalicylic Acid Delivery for Pancreatic Cancer via Conjugation wi… DOI 10.1021/acsabm.9b01068 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.